BACK TO ALL STUDIES

Rapidly Scalable COVID-19 Surveillance Program

PRIMARY OBJECTIVE(s)

Track the spread of the COVID-19 epidemic by syndromic surveillance and longitudinal serosurveillance in parts of the state covered by participating health care systems. Utilize Electronic Health Record data to further characterize the epidemic and to regularly monitor for sequelae of infection.

PRINCIPAL INVESTIGATOR(S)

David Herrington and John Sanders

CONTACT
David Herrington and John Sanders
jwsander@wakehealth.edu
TREATMENT/CLINICAL & LAB INVESTIGATION

1) Clinical and laboratory monitoring through EMR. 2) Serosurveillance utilizing at home testing or collection. 3) Viral testing utilizing at home collection.

POPULATION
Mult. Defined populations: 1. open enrollment for syndromic surveillance; 2. health system member for EM5R data pulls; 3. serosurveillance based on demographics (county, age, race, gender); high risk populations (i.e., HCW's, vulnerable populations, etc.)
FULL NAME OF DIAGNOSTIC TEST

1) Scanwell Health application using lateral flow assay (Syntron or Innovita). 2) Neoteryx mitra collection device at home process through LabCorp for EIA testing. 3) Viral testing utilizing Curative method (George Washington) or Yale method (Quest).

Lab Used for Diagnostic Test
Full Name of Serology/Antibody Test

1) Scanwell Health application using lateral flow assay (Syntron or Innovita). 2) Neoteryx mitra collection device at home process through LabCorp for EIA testing;

Lab Used for Serology/Antibody Test
LabCorp
Want more information about this study?
study website